Pfizer's Attempt to Return Bextra to European Market Rejected
After removing the Cox-2 drug Bextra from the marketplace in April, Pfizer recently applied to the European Medicines Agency to return Bextra to the European market. The Agency denied the application, citing the drugs serious cardiovascular risks and adverse skin reactions. Pfizer has expressed its intent to return Bextra to the market, but absent a showing of the drugs benefits outweighing the risks, this is unlikely.
Read the EMEA's statement here.
Post A Comment / Question